Nimenrix powder and solvent for solution for injection in pre-filled syringe Meningococcal groups A clinical trials
4 indexed studies · 0 currently recruiting
- AuthorisedTherapeutic use (Phase IV)
EarLy extra Measles immunisation during a measles Outbreak (ELMO)
This study looks at how well babies are protected from measles when they get their first measles vaccine (MMR-0) earlier than usual during a measles outbreak. Researchers will check their immunity levels and monitor for any side effects.
For: Healthy infants receiving a profylactic vaccine to prevent measles infectionNetherlands - Ongoing, recruitingHuman Pharmacology (Phase I)- Other
A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 months to < 24 months
This study is looking at how safe new vaccines are for babies aged 5 to 23 months. It's testing two different vaccines (mRNA-1345 and mRNA-1365) to see if they help protect against chest infections, like those caused by RSV. Scientists are checking for any side effects and how well the vaccines boost the babies' immune systems.
For: Acute lower respiratory infectionSpain · Latvia · Poland - Ongoing, recruitingPhase I and Phase II (Integrated)- Other
A Phase II, Randomized, Partially Blinded Study to Assess the Safety, Tolerability and Immunogenicity of Meningococcal Combined ABCWY Vaccine when Administered to Healthy Infants
This study is testing a new vaccine that aims to protect babies from serious illnesses like meningitis. The main goals are to see if it's safe, how well babies tolerate it, and if it helps their bodies build protection against these infections.
For: Infections · MeningococcalPoland · Spain · Germany - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A parallel-group, prevention, Phase III, modified double-blind, 2-arm, study to investigate the immunogenicity and describe the safety of a quadrivalent meningococcal conjugate vaccine (MenACYW conjugate vaccine) compared with Nimenrix® when administered in a 1+1 schedule in healthy infants and toddlers at 6 and 12 months of age
This study is looking at a new vaccine to protect babies and young children from meningococcal disease. We are comparing how well this new vaccine works and its safety compared to a current vaccine, Nimenrix, in healthy infants and toddlers in the UK.
For: Healthy volunteers (Meningococcal infection)Finland · Poland · Germany